Amgen Inc
Latest Amgen Inc News and Updates
Earnings ReportHow Does Vertex Plan to Expand Beyond Cystic Fibrosis?
Vertex is trying to expand its product base beyond cystic fibrosis. It holds molecules in the oncology, respiratory, pain, spinal cord, and influenza spaces. Company & Industry OverviewsCelgene Continues to Develop New Multiple Myeloma Drugs
Celgene has been working on its immunomodulatory backbone drugs to develop combination therapies for use in treating all lines of multiple myeloma. Company & Industry OverviewsWhy Did Amgen Implement Multi-Pronged Strategy for Repatha?
Amgen (AMGN) is expecting to strengthen Repatha’s brand position in the global cardiovascular market in 2016 through a multi-pronged strategy. Company & Industry OverviewsRomosozumab: Will It Benefit Amgen in the Future?
In 1Q16, Amgen expects to have data from its Phase 3 clinical trial exploring the use of innovative drug romosozumab for treating post-menopausal osteoporosis. Company & Industry OverviewsWhat Could Drive Amgen’s Kyprolis Sales in 2016?
Amgen expects Kyprolis to continue capturing the global multiple myeloma (or MM) market in 2016. The drug has established itself as a backbone therapy for relapsed MM. Earnings ReportAbbVie’s Net Profit Margin Expected to Reach 29.8% in 4Q15
AbbVie (ABBV) has continued to improve its operational efficiency, which is expected to result in a net profit margin of 29.8%, a YoY increase of 6.3%. In 3Q15, AbbVie realized a net proft margin of 30.4%. Earnings ReportRevlimid Continues to Drive Celgene’s Revenue
Revlimid (lenalidomide) is one of Celgene’s (CELG) main revenue drivers. It had revenues of $1.4 billion in 3Q15, excluding the adverse impact of foreign exchange fluctuations. Earnings ReportAbbVie’s Late-Stage Research Pipeline Could Boost Future Revenues
In partnership with Bristol-Myers Squibb, AbbVie is exploring elotuzumab to treat relapsed refractory multiple myeloma. The drug also received a breakthrough therapy designation from the FDA on May 19, 2014. Company & Industry OverviewsBioMarin’s Business Model and Its 3 Sources of Revenue
Let’s discuss BioMarin’s business model. It derives revenue from three sources, including product revenue. The latter accounts for ~98% of total revenue. MiscellaneousHow Would Kyndrisa Treat Duchenne Muscular Dystrophy?
The FDA advisory committee has given an unfavorable opinion to Kyndrisa. But most analysts estimate the probability of FDA approval for the drug to be about 50%. MiscellaneousKanuma: An Innovative Enzyme Replacement Therapy for LAL-D
Alexion Pharmaceuticals’ Kanuma is an innovative enzyme replacement therapy for patients suffering with lysosomal acid lipase deficiency (or LAL-D). MiscellaneousThe European Commission Approved Novartis’s Entresto
On November 24, Novartis announced that the European Commission had approved Entresto as a therapy for adult patients suffering from symptomatic chronic heart failure with reduced ejection fraction. Company & Industry OverviewsNovo Nordisk: An Investor’s Guide to a Leading Biotech Company
Novo Nordisk (NVO) is a leader in diabetes care with 90 years of experience coupled with a strong workforce of 39,700 in 75 countries around the world. Company & Industry OverviewsAlexion Pharmaceuticals’ Cost Structure and EBITDA Margins
Mature biotechnology companies generally earn EBITDA margins of about 30% to 40%. Company & Industry OverviewsVertex Pharmaceuticals’ Cost Structure and EBITDA Margins
While mature biotechnology companies with drugs in multiple disease segments earn an average of 30%–40% EBITDA, margins of companies targeting only rare diseases can vary due to unique business models. Company & Industry OverviewsAlexion Pharmaceuticals Diversifies Its Research Pipeline
Alexion Pharmaceuticals (ALXN) has strengthened its drug pipeline by diversifying its research programs across the metabolic disorder segment. Company & Industry OverviewsVertex Has Strong Research and Development Pipeline
As part of its research and development, Vertex Pharmaceuticals (VRTX) has been actively exploring new cystic fibrosis (or CF) drugs as well as other indications for its existing drug Kalydeco. Company & Industry OverviewsVertex Pharmaceuticals’ New Drug Orkambi Receives FDA Approval
On July 2, 2015, the FDA (U.S. Food and Drug Administration) approved Orkambi, a combination drug of lumacaftor and ivacaftor, for treating cystic fibrosis (or CF) patients. Company & Industry OverviewsVertex Pharmaceuticals’ 3-Pronged Business Model
Vertex Pharmaceuticals’ (VRTX) business model includes revenues in three areas: products, royalties, and collaboration. There’s significant variability in royalty and collaboration revenues. Company & Industry OverviewsAn Overview of AbbVie’s Business Model
AbbVie’s business model involves generating revenues through the sale of pharmaceutical products, which target some of the world’s most serious diseases. Company & Industry OverviewsAbbVie: An Investor’s Look at a Leading Biotechnology Company
With a market capitalization of $100.7 billion, AbbVie is a major US biopharmaceutical company. AbbVie competes with Amgen, Gilead Sciences, and Bristol-Myers Squibb . Company & Industry OverviewsAmgen’s Key Risks
Amgen’s key risks include market erosion due to generic competition for Neulasta and Neupogen. Its restructuring also involves a reduction of about 3,500–4,000 employees. Company & Industry OverviewsAmgen Develops World-Class Manufacturing Capability
Enhancing its manufacturing capability, Amgen has launched a next-generation bio-manufacturing facility in Singapore and plans to set up more in the coming years. Company & Industry OverviewsAmgen’s Presence in the Biosimilar Market
As it is still relatively difficult to introduce biosimilars, Amgen plans to enter the US market by leveraging experience of biosimilars in the European market. Company & Industry OverviewsAmgen’s Research and Development Strategy
Amgen (AMGN) has adopted a well-structured research and development strategy focused on inflammation, metabolism, bone, and cardiovascular diseases. Company & Industry OverviewsAmgen’s Presence in Inflammation, Nephrology, and Bone Segments
Amgen offers various nephrology drugs such as Epogen, Aranesp, Sensipar, and Mimpara. Both Epogen and Aranesp have been facing squeezed profits from tight competition. Company & Industry OverviewsRegeneron: An Investor’s Overview to a Leading Biotech Company
With a market capitalization of $50.7 billion, Regeneron is one of the country’s major biotechnology companies. Its products and pipeline candidates focus on cancer, eye diseases, and cardiovascular diseases. Company & Industry OverviewsAn Overview of Amgen’s Business Model
Amgen’s (AMGN) business model generates revenues in two ways: product sales and other revenues mainly comprised of royalties and corporate partner income. Company & Industry OverviewsAmgen: An Investor’s Overview to a Leading Biotech Company
An overview of global biotechnology company Amgen shows a market capitalization of $127.2 billion. Headquartered in Thousand Oaks, California, Amgen has a presence in 75 countries. Company & Industry OverviewsCelgene’s EBITDA Margins Surpass Competitors
Celgene’s EBITDA margins were lower than those of its competitors. Its R&D investment appears to be higher than its peers, and its SG&A expenses have risen. Company & Industry OverviewsIntroducing Celgene, a Leading Biotech Company
Celgene has consistently delivered breakthrough innovations in biotechnology and has as actively pursued acquisitions of companies for access to compounds. Company & Industry OverviewsAn Overview of Gilead Sciences’ Business Model
Gilead Sciences’ business model consists of product sales in the HIV and HCV markets, as well as royalty, contract, and other revenues. Company & Industry OverviewsGilead Sciences: Investor’s Overview of a Leading Biotech Company
The strong leadership of Gilead’s talented scientists has enabled the company to consistently deliver innovative therapies in the market. Company & Industry OverviewsBiogen: An Investor’s Overview to a Leading Biotech Company
One of the world’s leading biotechnology companies, Biogen specializes in manufacturing and marketing therapies to treat serious ailments related to the nervous system, immune system, and blood. Company & Industry OverviewsAn Overview of Biogen’s Business Model
A leader in the development of multiple sclerosis treatments, Biogen earned 82.5% of its total revenues from its MS drugs in 2014. Company & Industry OverviewsHow Does Competition Impact the Biotechnology Industry?
The biotechnology sector is witnessing intense competition with big pharmaceutical companies entering into collaborations and mergers and acquisitions with biotechnology companies. Company & Industry OverviewsHumira Takes Top Spot for Rheumatoid Arthritis Drugs
There’s no complete cure for rheumatoid arthritis, so most RA drugs are part of disease-management therapy. Humira accounts for 23.5% of the RA market share. Company & Industry OverviewsCommercial Growth Drivers of the Biotechnology Industry
After 2012, the biotechnology industry (IBB) had a period of solid growth, mainly driven by novel scientific inventions and aggressive commercial distribution. Company & Industry OverviewsBristol-Myers Squibb’s Immunoscience Franchise
Bristol-Myers Squibb’s (BMY) immunoscience franchise deals with medicines that help defend the body against invading pathogens like bacteria, viruses, and cancer cells. Company & Industry OverviewsPatents and the Biotechnology Sector
The biotechnology industry will witness 12 blockbuster drugs worth $67 billion in annual revenues lose their patents by 2020. This is the so-called patent cliff. Company & Industry OverviewsDrug Approval Process in the Biotechnology Industry
A drug approval process is required in order for a new drug to enter the market. Companies with new drugs in later stages of the approval process are more likely to earn a positive cash flow in the next few years. Company & Industry OverviewsSocial Factors That Impact the Biotechnology Industry
The aging Baby Boomer population in the United States is one of the social factors driving the US healthcare industry. By 2030, Americans over 55 will be 31% of the population. Company & Industry OverviewsEconomic Factors That Affect the Biotechnology Industry
Compared to pure-play pharmaceutical companies, the biotechnology industry is more sensitive to economic factors such as changes in GDP, interest rates, and exchange rates. Company & Industry OverviewsThe Business Models of Biotechnology Companies
The type of business model a biotechnology company selects depends on technical capability, availability of resources, and competition in the industry. Company & Industry OverviewsHow Are Drugs Classified?
The two main classifications for drugs are chemical compound drugs and biologics. Medicinal drugs are broadly classified as prescription drugs and over-the-counter drugs. Company & Industry OverviewsA Must-Read Overview of the US Biotechnology Industry
Biotechnology is simply ‘technology based on biology.’ The biotechnology industry includes food technology, genetic research, healthcare, and environmental technology.